<DOC>
	<DOCNO>NCT02905539</DOCNO>
	<brief_summary>The purpose study determine extend treatment iron compound Iron Isomaltoside 1000 Ferric Carboxymaltose lead hypophosphatemia study potential clinical impact hypophosphatemia .</brief_summary>
	<brief_title>A Study Comparing Iron Substitution With Medicinal Products Ferinject Monofer</brief_title>
	<detailed_description>Recent study suggest intravenous iron preparation anemia treatment may adverse effect phosphorus regulation , may induce increase phosphaturic hormone Fibroblast Growth Factor-23 ( FGF-23 ) subsequent fall plasma phosphorus level . So far unknown effect class- substance-specific . This study address question whether among female participant iron deficiency anemia application ferric- ( III ) -derisomaltose ferric carboxymaltose cause episodes hypophosphatemia extend . The investigator additionally compare effect two iron preparation parameter calcium-phosphate metabolism , decipher potential consequence hypophosphatemia analyse cardiac function , immunological parameter quality life . In order investigate outcome , 60 woman iron deficient anemia randomise receive either ferric- ( III ) -derisomaltose ferric carboxymaltose . The monocentric study conduct Saarland University Medical Center . For participate woman , study comprises five visit study center period five week .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>write informed consent , female , gynecological blood loss , age ≥ 18 year , iron deficiency anemia , Hemoglobin &lt; 12,0 g/dl , SerumFerritin ≤ 100 ng/ml SerumFerritin ≤ 300 ng/ml Transferrinsaturation ≤ 30 % , Intolerance inefficacy oral iron supplement estimate Glomerular Filtration Rate &gt; 15 ml/min/1.73 m² know hypersensitivity MonoFer® FERINJECT® , severe , know hypersensitivity intravenous iron preparation , Plasma Phosphate &lt; 2.5 mg/dl screening , Hemochromatosis , Untreated hyperparathyroidism , Renal replacement therapy/kidney transplantation , Active malignant disease , diseasefree survival le 5 year , Intravenous iron administration within last 30 day , Treatment erythropoietin erythropoietinstimulating agent , transfusion red blood cell , radiotherapy chemotherapy within last 60 day , Surgery anesthetic within last 10 day , Alanine transaminase ( ALT ) aspartate transaminase ( AST ) &gt; 1.5 fold level healthy individual , Acute febrile infection within last 7 day , Chronic inflammatory disease require systemic antiinflammatory treatment , selfreported severe asthma eczema , presence relative contraindication ( allergy , immunologic inflammatory disease , history atopic allergy ) , treatment medicinal investigational product deem indicated investigator , pregnancy , woman childbearing potential without effective method contraception , lactate woman , Present alcohol drug dependency , Patients history psychological illness seizure , Noncompliance administration investigational drug within 30 day precede study start .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Iron</keyword>
	<keyword>anemia</keyword>
	<keyword>phosphorus</keyword>
	<keyword>FGF-23</keyword>
</DOC>